
HPV

Renee E. Mestad, MD, MSCI
Assistant Professor
SUNY Upstate Dept. of Ob/Gyn



Human

Papilloma

Virus

EPIDEMIOLOGY

- 80% of people infected
- Most common STI
- 150 virus types
- Skin-to-skin contact
- Males and females
- Not always visible
- 33,000 cancers in men and women

HPV is a common virus that infects teens and adults.



80%

of people will get an HPV infection in their lifetime.

MANIFESTATION

- Hand and foot warts
- Genital warts
- Cancer
 - Cervical
 - Vaginal
 - Vulvar
 - Penile
 - Oropharyngeal
 - Anal



ONCOGENICITY

High Risk


- 16, 18, 31, 33, 35, 45, 58
- 95% cervical cancers
- 16, 18-70%
- 16 most carcinogenic

Low Risk

- 6, 11
- Most genital warts

TRANSMISSION

- Skin-to-skin
- Homosexual women have same risk as heterosexual
- Perinatal
 - Rare
 - 1-3 yrs of age
 - Conjunctival, laryngeal, vulvar, peri-anal
 - c/s not recommended
 - Consider sexual abuse after infancy



NATURAL HISTORY

	Regression (%)	Persistence (%)	Progression to CIS (%)	Progression to Invasion (%)
CIN 1	57	32	11	1
CIN 2	43	35	22	5
CIN 3	32	<56	_	>12

CERVICAL INTRAEPITHELIAL NEOPLASIA

- Mild dysplasia
 - CIN 1
 - LGSIL
- Moderate dysplasia
 - CIN 2
- Severe dysplasia
 - CIN 3
 - HGSIL

NATURAL HISTORY

- 46% demonstrate cervical infection within 3 yrs of debut
- Median time to infection is 3 mos
 - Likely indicates sexual activity, not promiscuity
- Most resolve in young women
 - Many different infections
 - Likely sequential infection with new partners
- Low risk resolve faster than high risk
- Infection in older women is likely persistent
 - Risk of progression increases with age

RISK FACTORS

- Low socioeconomic status
- Age
- Early sexual debut
- Smoking
- Multiple partners

- Dietary deficiencies
- HRHPV infection
- Exogenous hormones
- Immune suppression
- Lack of screening

TESTING

Screening

- Asymptomatic
- Low cost
- Used broadly
- Low risk/invasive
- High sensitivity
- Identify people needing diagnosis

Diagnostic


- Symptomatic
- Higher cost
- Used narrowly
- Higher risk/invasive
- Specific
- Identify people needing treatment







THE PAP SMEAR




THE PAP SMEAR

MANAGEMENT

- Conservative
- Colposcopy
- LEEP
 - Loop Electrocautery Excision Procedure
- Cold knife cone
- Hysterectomy





COLPOSCOPY

Loop Electrosurgical Excision Procedure (LEEP) Half-way through the LEEP Procedure Notice that the specimen includes the abnormal-appearing tissue Kenyaram Appearance of Cervix at the end of the LEEP procedure Abnormal Cells Note that the tissue removed is sent for analysis. LEEP Wire Removed Tissue Kryaron Appearance of the cervix 6 weeks postoperatively Kenyarama

LEEP

Population	Recommended Screening Method	Comment	
Women younger than 21 years	No screening		
Women aged 21–29 years	Cytology alone every 3 years		
Women aged 30–65 years	Human papillomavirus and cytology cotesting (preferred) every 5 years Cytology alone (acceptable) every 3 years	Screening by HPV testing alone is not recommended*	
Women older than 65 years	No screening is necessary after adequate negative prior screening results	Women with a history of CIN 2, CIN 3, or adenocarcinoma in situ should continue routine age-based screening for a total of 20 years after spontaneous regression or appropriate management of CIN 2, CIN 3, or adenocarcinoma in situ	
Women who underwent total hysterectomy	No screening is necessary	Applies to women without a cervix and without a history of CIN 2, CIN 3, adenocarcinoma in situ, or cancer in the past 20 years	
Women vaccinated against HPV	Follow age-specific recommendations (same as unvaccinated women)		

PAP SMEAR SCHEDULE

Screening Method	Result	Management	
Cytology screening alone	Cytology negative	Screen again in 3 years	
	ASC-US cytology and reflex HPV negative	Cotest in 3 years	
	All others	Refer to ASCCP guidelines*	
Cotesting	Cytology negative, HPV negative	Screen again in 5 years	
	ASC-US cytology, HPV negative	Screen again in 3 years	
	Cytology negative, HPV positive	Option 1: 12-month follow-up with cotesting	
		Option 2: Test for HPV-16 or HPV-18 genotypes	
		 If positive results from test for HPV-16 or HPV-18, referral for colposcopy 	
		 If negative results from test for HPV-16 and HPV-18, 12-month follow-up with cotesting 	
	All others	Refer to ASCCP guidelines*	

SCREENING ALGORITHM







PREVENTION

PREVENTION




31,200





cases of cancer could be prevented with HPV vaccination each year. Same as the average attendance for a baseball game.





HPV VACCINE



- Males and females 9-26
- 2 doses if first dose under age 15 yrs
 - Baseline and at 6-12 mos
- 3 doses if first dose 15 or older
 - Baseline, 1-2 mos, and at 6 mos
- 2, 4, 9 HPV types
- Not approved for people older than 26
- Can be used for immune suppressed
- Few adverse reactions

CLOSING STATISTICS

- Cervical cancer once the leading cause of cancer deaths
- Mortality declined 50% in 40 years
- 2017- 12,820 women diagnosed
- 4,210 died
- Most diagnosed between ages 20-50

